Literatur zum Artikel:

Kardiale Amyloidose

von PD Dr. Maria Papathanasiou, Dr. med. Lukas Zanders, Dr. med. Lara S. Schlender, Univ.-Prof. Dr. med. David M. Leistner

Adams D, et al. Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment. Lancet Neurol 2023;22:1061–1074.

Aimo A, et al. Sex differences in transthyretin cardiac amyloidosis. Heart Fail Rev 2024;29:321–330.

Fontana M, et al. Vutrisiran in Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2024.

Garcia-Pavia P, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the European Society of Cardiology. Eur J Heart Fail 2021;23:512–526.

Garcia-Pavia P, et al. Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N Engl J Med 2023;389:239–250.

Gertz MA, et al. Systemic Amyloidosis: Recognition, Prognosis, and Therapy. JAMA 2020.

Gillmore JD, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med 2021;385:493–502.

Gillmore JD, et al. Long-term TTR reduction with CRISPR-Cas9 gene editing in transthyretin amyloidosis. N Engl J Med 2024.

Griffin JM, et al. Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. Circ Res 2021;128:1554–1575.

Grogan M, et al. Artificial Intelligence-Enhanced Electrocardiogram for the Early Detection of Cardiac Amyloidosis. Mayo Clin Proc 2021;96:2768–2778.

Hourmozdi J, et al. Evaluating the Performance and Potential Bias of Predictive Models for Detection of Transthyretin Cardiac Amyloidosis. JACC Adv 2025;4:101901.

Ioannou A, et al. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J 2023;44:2893–2907.

Jain SS, et al. Detecting Transthyretin Cardiac Amyloidosis With Artificial Intelligence: A Nonrandomized Clinical Trial. JAMA Cardiol 2026;11:117–124.

Kastritis E, et al. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med 2021;385:46–58.

Jering KS, et al. Effects of Transthyretin Stabilization on Cardiac Structure and Function in ATTR-CM. Nat Med 2025.

Kittleson MM, et al. Transthyretin Cardiac Amyloidosis Evaluation and Management:2025 ACC Concise Clinical Guidance. J Am Coll Cardiol 2025.

Maurer MS, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2018;379:1007–1016.

Mohammed SF, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014;2:113–122.

Nitsche C, et al. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. J Am Coll Cardiol 2021;77:128–139.

Oikonomou EK, et al. Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy. Eur Heart J 2025;46:3651–3662.

Papathanasiou M, et al. Quantitative nuclear imaging for assessment of amyloid burden and therapy response in cardiac ATTR amyloidosis. J Nucl Med 2023.

Porcari A, et al. SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol 2024;83:2411–2422.

Ruberg FL, et al. Cardiac Amyloidosis Due to Transthyretin Protein: A Review. JAMA 2024.

Sanchorawala V. Systemic Light Chain Amyloidosis. N Engl J Med 2024;390:2295–2307.

Sanchorawala V, et al. A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of Amyloidosis. Amyloid 2025;32:303–308.

Slivnick JA, et al. Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool. Eur Heart J 2025;46:4090–4101.

Tanskanen M, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008;40:232–239.

Treibel TA, et al. Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. Circ Cardiovasc Imaging 2016;9:e005066.

Literatur zum Artikel:

Der Safety Plan für Jugendliche in suizidalen Krisen

Suizidales Verhalten im Jugendalter – Serie Teil 5

von Prof. Dr. med. Katja Becker, Dr. med. Anna Anschlag und Dr. rer. med. Daria Kasperzack

[1] Voss C, Ollmann TM, Miché M, Venz J, Hoyer J, Pieper L et al. Prevalence, onset, and course of suicidal behavior among adolescents and young adults in Germany. JAMA Network Open 2019;2(10).

[2] Kasperzack D, König U, Becker K. Die Entwicklung der Suizidzahlen von Kindern und Jugendlichen in Deutschland von 2005 bis 2023. Z Kinder Jugendpsychiatr Psychother 2026;54(2):90–99. doi:10.1024/1422–4917/a001067.

[3] Becker K, Kasperzack D. Suizidales Verhalten im Jugendalter: Besser verstehen, besser versorgen. Editorial. Z Kinder Jugendpsychiatr Psychother 2026;54(2):65–68. doi:10.1024/1422–4917/a001070.

[4] Anschlag A, Cosan AS, Becker K, Kasperzack D. Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung und suizidales Verhalten. Ein unterschätztes Risiko. Die Psychotherapie 2025;70:215–224. doi:10.1007/s00278–025–00779–0.

[5] Kasperzack D, Becker K. Emotionsregulation bei Jugendlichen mit sozialer Angststörung, Depression, selbstverletzenden Verhaltensweisen und suizidalem Verhalten. Die Psychotherapie 2025;70:207–214. doi:10.1007/s00278–025–00780–7.

[6] Becker M, Correll CU. Suizidalität im Kindes- und Jugendalter – hinsehen, verstehen, angemessen handeln. Psychother Dialog. 2026;27:23–29. doi:10.1055/a-2643–2452.

[7] Becker K, Anschlag A, Kasperzack D. Der Safety-Plan als (ergänzende) Kurzintervention für Jugendliche mit suizidalem Verhalten. Z Kinder Jugendpsychiatr Psychother 2026;54(2):100–110. doi:10.1024/1422–4917/a001051.

[8] DGPPN, DGKJP, DEGAM, DÄVT, DGAI, DGBP et al. S3-Leitlinie Umgang mit Suizidalität. Geplante Fertigstellung Ende 2026/Anfang 2027.

[9] Stanley B, Brown GK. Safety Planning Intervention: A brief intervention to mitigate suicide risk. Cogn Behav Pract 2012;19(2):256–264.

[10] Abbott-Smith S, Ring N, Dougall N, Davey J. Suicide prevention: What does the evidence show for the effectiveness of safety planning for children and young people? A systematic scoping review. J Psychiatr Ment Health Nurs 2023;30(5):899–910.

[11] Albaum C, Irwin SH, Muha J, Schumacher A, Clarissa S, Finkelstein Y et al. Safety Planning Interventions for Suicide Prevention in Children and Adolescents: A Systematic Review and Meta-Analysis. JAMA Pediatr. 2025;179(8):886–895. doi:10.1001/jamapediatrics.2025.1012.

[12] May A, Al-Dajani N, Ballard ED, Czyz E. Safety plan use in the daily lives of adolescents after psychiatric hospitalization. Suicide Life Threat Behav 2023;53(5):870–879.

Literatur zum Artikel:

Künstliche Intelligenz bei Seltenen Erkrankungen – Gegenwart und Zukunft

von Prof. Dr. Jannik Schaaf und Michaela C. Neff

[1] Ronicke S, Hirsch MC, Türk E, Larionov K, Tientcheu D, Wagner AD. Can a decision support system accelerate rare disease diagnosis? Evaluating the potential impact of Ada DX in a retrospective study. Orphanet Journal of Rare Diseases. 21. März 2019;14(1):69. doi:10.1186/s13023-019-1040-6

[2] Neff MC, Schütze D, Holtz S, Köhler SM, Vasseur J, Ahmadi N, u. a. Development and expert inspections of the user interface for a primary care decision support system. International Journal of Medical Informatics. 1. Dezember 2024;192:105651. doi:10.1016/j.ijmedinf.2024.105651

[3] Noll R, Berger A, Facchinello C, Stratmann K, Schaaf J, Storf H. Enhancing diagnostic precision for rare diseases using case-based reasoning. J Am Med Inform Assoc. 1. Januar 2026;33(1):98–111. doi:10.1093/jamia/ocaf092

[4] Weber MT, Noll R, Marchl A, Facchinello C, Grünewaldt A, Hügel C, u. a. MedBot vs RealDoc: efficacy of large language modeling in physician-patient communication for rare diseases. J Am Med Inform Assoc. 1. Mai 2025;32(5):775–83. doi:10.1093/jamia/ocaf034